Rep. Porter calls on HHS inspector general to investigate FDA-Biogen ties prior to Aduhelm's approval
Following the House Oversight Committee’s call to investigate the approval and price of Biogen’s new Alzheimer’s drug, Rep. Katie Porter (D-CA) is now calling on HHS’ inspector general to investigate the cozy relationship between the FDA and Biogen ahead of that approval.
The fallout over the Aduhelm approval continues in her letter Tuesday as Porter calls for a full review of all agency practices in meeting with pharmaceutical companies and to establish new internal policies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.